Member Info for sadoldgit

I for one, certainly hope that you are fine Thoth.
Regards

Congratulations on that achievement.

Good morning Fadec, yes a very interesting article indeed. I do note the following with regards to treatments too.

23 October — Promising drug for COVID-19 does not save lives

A study of a drug that mutes the body’s immune response found that it did not prevent the deaths of people with moderate COVID-19, dealing a blow to a once-popular hypothesis about treatments for the disease.

In some people with severe COVID-19, the immune system launches an excessive inflammatory response, suggesting a link between grave illness and an overly vigorous immune defence against SARS-CoV-2. The link is bolstered by the association between high levels of a protein called IL-6, which stimulates the immune system, and both death and the need for ventilation in people with COVID-19.

John Stone at the Massachusetts General Hospital in Boston and his colleagues tried to dampen inflammation in people with COVID-19 by treating them with the drug tocilizumab, which interferes with IL-6 activity (J. H. Stone et al. N. Engl. J. Med. https://doi.org/ffjp; 2020). But in a randomized, controlled trial of 243 people with moderate disease, the team found no statistically significant reduction in deaths or the need for ventilation among those who received tocilizumab compared with those who didn’t. The study does not rule out the possibility that a larger trial with more statistical power could uncover a benefit.

It does not mean Covid-19 cannot be treated. It just means that that current treatment tested on a few patients has not statistically proven effective. Clearly it may prove that it not selective enough.

I will put this message up again. It is Tims actual words from the Proactive interview with regards to FLT3. I have omitted to put in all the ' erms'.

'We came across a formulation issue which we did not really have the bandwidth or the expertise to resolve. But we have found a partner in China who have taken it on and work is progressing.
So, in the contract there is a milestone payable within 9 months of them receiving all the programme data, so that works out at early 2021, That is 900,000 milestone, but potentially available from that, assuming they meet the criteria or, or or choose just to carry on with it anyway, if they have just missed the actual value of the experiments they are looking to do, they could choose just to continue or just carry on with it anyway and pay the milestone.'

Very much like our TYK2 in that it shows efficacy in disease models has very good tolerability and very low toxicology , irrespective of whether it is used as a treatment for Covid or not. I suspect they are using it in some form against Covid 19

Formulation issues will not be a problem when the treatment of Covid 19 can be administered iv.

Regards

Good afternoon Andy. Best post of the day lad. I will say no more.
Regards

Yes RMM it a game to them. Up a few percent then drop down again to encourage actual sells. Mop a few shares up at a much lesser price to replace the ones they had agreed to transact. Little red dot should do nicely in the next coming few day/weeks. Me thinks they are trying to keep the price down. if they raise to much then there will be too many sells and not enough buyers and the price becomes very volatile. 3% a day up until the New year will do me.
Regards

He may well do over a morning coffee. But, I think you will find he would have already done his research into the company first.

Nothing to do whether bought or sold. Below mid price will show as a sell and above mid price will show as a buy. At the time the trade is executed.

I will add that Sierra will be looking to increase funds for continued development Momelotinib . These funds could be raised on the 'On licensing' of SRA737. So surely must now be down to negotiation between Gilead and Sierra.

Andy that would be absolutely great when you get a reply.

Ps I think Gilead have got hold of Sierra by the testicles

Regards

License Agreements
In September 2016, the Company entered into an exclusive license agreement with CRT Pioneer Fund LP (CPF) for worldwide rights, know-how and
materials to develop SRA737, a small molecule inhibitor targeting Chk1, a promising therapeutic target to treat cancer. Pursuant to the agreement, the
Company made a one-time upfront payment of $7.0 million to CPF in October 2016 and paid $2.0 million to CPF in January 2017 for the successful
transfer of two ongoing Phase 1 clinical trials. Additional milestone payments of up to an aggregate of $319.5 million may become payable to CPF upon
the achievement of certain developmental, regulatory and commercial milestones, including a milestone payment of $7.5 million upon the dosing of the
first patient in the first Phase 1 trial of SRA737 in the United States, and a payment of $12.0 million upon the dosing of the first patient of a randomized
Phase 2 trial of SRA737. In the event that the milestone payment for Phase 2 becomes due, but no milestone payment for Phase 1 has been paid, then the
milestone payment for Phase 1 will become due and payable contemporaneously with the payment for the Phase 2 milestone for an aggregate payment of
$19.5 million. These milestones will be accrued once they are considered probable of occurring. In addition, the Company is required to pay CPF, on a
product-by-product and country-by-country basis, tiered high single-digit to low double-digit royalties on the net sales of any product successfully
developed.

I think you are spot on there Andy. They cant afford the continued development at the same time they do not want to give it up. As sierra said themselves SRA737 could prove more commercially viable than Momelitinib, After all it has far more potential, a far greater market and sharks waiting to take it off their hands for a song. I would have thought that Gilead who they have close ties with would have seized on the opportunity. Sierra I feel have overcooked themselves. Sooner or later it will be either raise funds to develop CHK1, on license, or hand back with millions that has cost to develop so far.
As to what the CPF have to say on the matter, or what their intentions are God knows.
Regards

After reading that and knowing that Sareum have Tyk2 compound with JAk 1, a non achieved maximum tolerated dose then that must put 120 million on the market cap as it stands. This company is grossly undervalued!

I do not have a crystal ball.
I would hazard a guess at somewhere 6 to 12% up on the day.

What I think you will find is some large delayed trades at the end of the day.

When positive news does arrive, It will go up substantially.
When the news arrives is anybody's guess at the moment.

Tim was looking to license TYK 2 by year end.

I suggest you read through the Sareum archives and get an understanding of what the potential of the compounds of Sareum are.

Look at similar deals with pharmas and note carefully that we are at the late preclinical stage with TYK2, in addition to the potential as a life threatening treatment for the cytokine storm caused by Covid 19, of which we have recently received a grant for. If found suitable for treatment then SP many times what it is now.
Yes there are ifs and buts which will cause doubt. If there were not then the SP would be much higher than it is now.
Judge the risk against the reward.
The price will be volatile until news is released you can bet your bottom dollar on that one.
At the end of the day, it is your decision to sell or buy, sell on a profit, or sell on a profit and hope to get back in should the price fall.

Regards and please do some research yourself.

Andy, surely they would now have plans, almost to the point of execution with what they intend doing with SRA 737. 5 hit in the pot or get off so as to speak. They have been delaying for months. Clearly they do not want to lose the CHK1 and neither on license, at a loss to themselves. The potential of SRA737 has been held back drastically both in terms of discontinuing, to finance their Momeletinib and their inability to seek a new partner( which would require us being paid the circa 5million milestone) to continue the development into clinical use.
Regards

It could not wait to get out. Now it cannot wait to get back in again. So if you have 'sold a dummy', Why would you want to buy the dummy back?
A retrace of such back from 3p is expected. How low it goes before any news is released we will just have to wait and see.
Regards and good luck

Premium is off to with regards to chat

https://endpts.com/shares-sink-after-jounce-reports-a-phii-wont-be-continued-in-pd-l1-resistant-nsclc/

From Tims interview with Proactive investors.

Sareum Holdings focused on striking a deal for its immunotherapies.

We came across a formulation issue which we did not really have the bandwidth or the expertise to resolve. But we have found a partner in China who have taken it on and work is progressing.
So, in the contract there is a milestone payable within 9 months of them receiving all the programme data, so that works out at early 2021, That is 900,000 milestone, but potentially available from that, assuming they meet the criteria or, or or choose just to carry on with it anyway, if they have just missed the actual value of the experiments they are looking to do, they could choose just to continue or just carry on with it anyway and pay the milestone.

I am sure that the 900k would be paid if they chose to continue development. I will be back with further news on that, Smooth talking aussie interview.